[Pubmed] Distinct mechanisms underlying therapeutic potentials of CD20 in neurological and neuromuscular disease

[RSS-Bot]

Pharmacol Ther. 2022 Mar 31:108180. doi: 10.1016/j.pharmthera.2022.108180. Online ahead of print.

ABSTRACT

Cluster of differentiation 20 (CD20) is an integral membrane protein expressed mainly on different developmental stages of B lymphocytes and rarely on T lymphocytes, and it functions as a link to B cell antigen receptor (BCR) and immune microenvironment via regulating calcium ion influx, cell cycle progression and interaction between isotypic BCRs and their co-receptors. Diverse therapeutic monoclonal antibodies (mAbs) targeting CD20 are generated and grouped into two types based on the ability to redistribute CD20 into lipid rafts, which results in huge differences in response. Currently, multiple anti-CD20 mAbs have been approved as drugs for neurological and neuromuscular diseases with promising clinical efficacy. This review aims to summarize the potential mechanisms, development and current evidence for anti-CD20 therapy in neurological and neuromuscular diseases.

PMID:35367516 | DOI:10.1016/j.pharmthera.2022.108180


Source: https://pubmed.ncbi.nlm.nih.gov/3536751 ... 2&v=2.17.6